Global Bronchopulmonary Dysplasia 麻豆原创 Research Report 2023

Publication ID:

PB502234861

Publication Date:

February 7, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Bronchopulmonary dysplasia, a type of chronic lung disorder, affects newborns, mostly premature and infants. Lungs and bronchi are damaged at the neonatal phase which causes destruction of tiny air sacs known as alveoli. Babies are not born with the disease. The condition is developed when premature infants need aid to breathe for a longer period, leading to inflammation and lung scarring. Infants with this disease exhibit signs and symptoms such as rapid breathing and faster heart rate.听The disease is life threatening however, the severity of the disease varies.
Highlights
The global Bronchopulmonary Dysplasia market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The global bronchopulmonary dysplasia treatment market is expected to expand at a steady CAGR during the forecast period. According to the Journal of Clinical Medicine, 10,000 to 15,000 new cases of the disorder are reported each year in the U.S. alone. High prevalence of the diseases is expected to drive the global bronchopulmonary dysplasia treatment market during the forecast period. According to the WHO, 15 million babies are born preterm which is another factor contributing to the growth of the market. Furthermore, government initiatives, favorable reimbursement policies, launch of novel drugs, strong pipeline, rising premature birth cases, and increase in health care expenditure are factors likely to propel the global bronchopulmonary dysplasia treatment market during the forecast period. Long-term side effects of drugs, high cost of treatment, and lack of awareness in developing countries are factors anticipated to restrain the global market during the forecast period.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Bronchopulmonary Dysplasia, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bronchopulmonary Dysplasia.
The Bronchopulmonary Dysplasia market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Bronchopulmonary Dysplasia market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bronchopulmonary Dysplasia companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Chiesi Farmaceutici
Discovery Laboratories
Takeda Pharmaceutical Company
MediPost
Clarassance
Syntrix Biosystems
Segment by Type
Surfactant Replacement Therapy
Oxygen Therapy
Supportive Therapy
Others
Segment by Application
Clinic
Hospital
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Bronchopulmonary Dysplasia companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Bronchopulmonary Dysplasia 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Surfactant Replacement Therapy
1.2.3 Oxygen Therapy
1.2.4 Supportive Therapy
1.2.5 Others
1.3 麻豆原创 by Application
1.3.1 Global Bronchopulmonary Dysplasia 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Bronchopulmonary Dysplasia 麻豆原创 Perspective (2018-2029)
2.2 Bronchopulmonary Dysplasia Growth Trends by Region
2.2.1 Global Bronchopulmonary Dysplasia 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Bronchopulmonary Dysplasia Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Bronchopulmonary Dysplasia Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Bronchopulmonary Dysplasia 麻豆原创 Dynamics
2.3.1 Bronchopulmonary Dysplasia Industry Trends
2.3.2 Bronchopulmonary Dysplasia 麻豆原创 Drivers
2.3.3 Bronchopulmonary Dysplasia 麻豆原创 Challenges
2.3.4 Bronchopulmonary Dysplasia 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Bronchopulmonary Dysplasia Players by Revenue
3.1.1 Global Top Bronchopulmonary Dysplasia Players by Revenue (2018-2023)
3.1.2 Global Bronchopulmonary Dysplasia Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Bronchopulmonary Dysplasia 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Bronchopulmonary Dysplasia Revenue
3.4 Global Bronchopulmonary Dysplasia 麻豆原创 Concentration Ratio
3.4.1 Global Bronchopulmonary Dysplasia 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Bronchopulmonary Dysplasia Revenue in 2022
3.5 Bronchopulmonary Dysplasia Key Players Head office and Area Served
3.6 Key Players Bronchopulmonary Dysplasia Product Solution and Service
3.7 Date of Enter into Bronchopulmonary Dysplasia 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Bronchopulmonary Dysplasia Breakdown Data by Type
4.1 Global Bronchopulmonary Dysplasia Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Bronchopulmonary Dysplasia Forecasted 麻豆原创 Size by Type (2024-2029)
5 Bronchopulmonary Dysplasia Breakdown Data by Application
5.1 Global Bronchopulmonary Dysplasia Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Bronchopulmonary Dysplasia Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Bronchopulmonary Dysplasia 麻豆原创 Size (2018-2029)
6.2 North America Bronchopulmonary Dysplasia 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Bronchopulmonary Dysplasia 麻豆原创 Size by Country (2018-2023)
6.4 North America Bronchopulmonary Dysplasia 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Bronchopulmonary Dysplasia 麻豆原创 Size (2018-2029)
7.2 Europe Bronchopulmonary Dysplasia 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Bronchopulmonary Dysplasia 麻豆原创 Size by Country (2018-2023)
7.4 Europe Bronchopulmonary Dysplasia 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Bronchopulmonary Dysplasia 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Bronchopulmonary Dysplasia 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Bronchopulmonary Dysplasia 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Bronchopulmonary Dysplasia 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Bronchopulmonary Dysplasia 麻豆原创 Size (2018-2029)
9.2 Latin America Bronchopulmonary Dysplasia 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Bronchopulmonary Dysplasia 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Bronchopulmonary Dysplasia 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Bronchopulmonary Dysplasia 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Bronchopulmonary Dysplasia 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Bronchopulmonary Dysplasia 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Bronchopulmonary Dysplasia 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Chiesi Farmaceutici
11.1.1 Chiesi Farmaceutici Company Detail
11.1.2 Chiesi Farmaceutici Business Overview
11.1.3 Chiesi Farmaceutici Bronchopulmonary Dysplasia Introduction
11.1.4 Chiesi Farmaceutici Revenue in Bronchopulmonary Dysplasia Business (2018-2023)
11.1.5 Chiesi Farmaceutici Recent Development
11.2 Discovery Laboratories
11.2.1 Discovery Laboratories Company Detail
11.2.2 Discovery Laboratories Business Overview
11.2.3 Discovery Laboratories Bronchopulmonary Dysplasia Introduction
11.2.4 Discovery Laboratories Revenue in Bronchopulmonary Dysplasia Business (2018-2023)
11.2.5 Discovery Laboratories Recent Development
11.3 Takeda Pharmaceutical Company
11.3.1 Takeda Pharmaceutical Company Company Detail
11.3.2 Takeda Pharmaceutical Company Business Overview
11.3.3 Takeda Pharmaceutical Company Bronchopulmonary Dysplasia Introduction
11.3.4 Takeda Pharmaceutical Company Revenue in Bronchopulmonary Dysplasia Business (2018-2023)
11.3.5 Takeda Pharmaceutical Company Recent Development
11.4 MediPost
11.4.1 MediPost Company Detail
11.4.2 MediPost Business Overview
11.4.3 MediPost Bronchopulmonary Dysplasia Introduction
11.4.4 MediPost Revenue in Bronchopulmonary Dysplasia Business (2018-2023)
11.4.5 MediPost Recent Development
11.5 Clarassance
11.5.1 Clarassance Company Detail
11.5.2 Clarassance Business Overview
11.5.3 Clarassance Bronchopulmonary Dysplasia Introduction
11.5.4 Clarassance Revenue in Bronchopulmonary Dysplasia Business (2018-2023)
11.5.5 Clarassance Recent Development
11.6 Syntrix Biosystems
11.6.1 Syntrix Biosystems Company Detail
11.6.2 Syntrix Biosystems Business Overview
11.6.3 Syntrix Biosystems Bronchopulmonary Dysplasia Introduction
11.6.4 Syntrix Biosystems Revenue in Bronchopulmonary Dysplasia Business (2018-2023)
11.6.5 Syntrix Biosystems Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Chiesi Farmaceutici
Discovery Laboratories
Takeda Pharmaceutical Company
MediPost
Clarassance
Syntrix Biosystems

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.